All In Biotech

Drug Trial Radar · NCT07527858

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

May 19, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).

Conditions

  • Advanced Microsatellite Stable Colorectal Cancer

Interventions

  • DenikitugDrug

    Administered Intravenously

  • NivolumabDrug

    Administered Intravenously

  • BevacizumabDrug

    Administered Intravenously

  • Trifluridine-TipiracilDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to 60 months

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Yale-New Haven Hospital - Yale Cancer Center

    North Haven, Connecticut · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • University of Virginia,

    Charlottesville, Virginia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, CA, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Samsung Medical Center

    Busan, South Korea · Not yet recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Yonsei University Severance Hospital ( aka Yonsei Cancer Center)

    Seoul, South Korea · Not yet recruiting

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.